Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Summary

This is a first in human, non-randomized, open-label, dose escalation study to investigate the safety, pharmacokinetics, immunogenicity and pharmacodynamics of repeat doses of KHK2823.

Timeline

Start

2014-06

Primary completion

2019-05-10

Completion

2019-05-10

Outcome

Outcome not reported

Stopped: “Failed treatment response”

Drugs

Indications